Distinct Molecular and Prognostic Profiles of Left‐ and Right‐Sided Colorectal Cancer Revealed by NGS Analysis: The Role of SMAD4 and SETD2 Mutations
Cancer Medicine · 2026
DOI: 10.1002/cam4.71534 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Wenlei Zhao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, First Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Smad4 Protein, Mutation, Colorectal Neoplasms, Histone-Lysine N-Methyltransferase. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Colorectal cancer (CRC) isthe third most common cancer and the second leading cause of cancer‐relateddeath worldwide. Its genetic heterogeneity complicates treatment. This studyaimed to compare clinicopathological, molecular, and prognostic factors betweenleft‐sided (LCC) and right‐sided (RCC) CRC.
Methods
We retrospectively analyzed 48 CRCpatients who received next‐generation sequencing (NGS) of tumor tissue andmatched leukocytes using a 425‐gene panel. Clinicopathological, molecular, andprognostic factors were compared between LCC and RCC.
Results
RCC exhibited a higher frequencyof BRAF mutations (33.3% vs. 7.1%, p = 0.042) and more frequent alterations in PI3K ( p = 0.033), homology‐dependent recombination (HDR, p = 0.018), and mismatch repair (MMR, p = 0.002) pathways than LCC. Multivariate analysis identified SMAD4 mutation as an independentpredictor of worse overall survival (OS) (HR = 3.88, 95% CI 1.05–14.29, p = 0.042), which was confirmed in an external cohort of 1796 CRCpatients. In subgroup analyses, SETD2 mutationswere associated with poor prognosis in LCC (HR = 2.20, 95% CI 0.80–6.06, p = 0.026), while ARID1A ( p = 0.040) and PRDM1 ( p = 0.021) mutations correlated with shorter progression‐free survival in RCC. Patients harboring both SMAD4 and SETD2 mutationshad the shortest OS (median: 17.7 months, p < 0.0001).
Conclusions
These findings reveal criticalmolecular and prognostic differences between LCC and RCC and highlight SMAD4 and SETD2 asimportant prognostic biomarkers, suggesting the potential value of location‐and mutation‐guided precision therapies in CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, First Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
- Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China.
ORCID-Profile: Wenlei Zhao, Yuxuan Qiu, Feng Liang
Zitieren
APA
Zhao, W., Qiu, Y., Bai, N., He, C., Yin, J. C., Xu, Q., Jian, K., Jia, B., Jiang, L., & Liang, F. (2026). Distinct Molecular and Prognostic Profiles of Left‐ and Right‐Sided Colorectal Cancer Revealed by NGS Analysis: The Role of SMAD4 and SETD2 Mutations. Cancer Medicine. https://doi.org/10.1002/cam4.71534
Vancouver
Zhao W, Qiu Y, Bai N, He C, Yin JC, Xu Q, et al. Distinct Molecular and Prognostic Profiles of Left‐ and Right‐Sided Colorectal Cancer Revealed by NGS Analysis: The Role of SMAD4 and SETD2 Mutations. Cancer Medicine. 2026. doi:10.1002/cam4.71534
BibTeX
@article{Zhao2026,
author = {Zhao, Wenlei and Qiu, Yuxuan and Bai, Na and He, Chunhong and Yin, Jiani C and Xu, Qianru and Jian, Kaiyu and Jia, Baolei and Jiang, Lin and Liang, Feng},
title = {Distinct Molecular and Prognostic Profiles of Left‐ and Right‐Sided Colorectal Cancer Revealed by NGS Analysis: The Role of SMAD4 and SETD2 Mutations},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.71534}
}
EUVIMED